- Home
- NVTS vs KROS Comparison
NVTS vs KROS Comparison
Compare NVTS & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVTS
- KROS
- Stock Information
- Founded
- NVTS 2014
- KROS 2015
- Country
- NVTS United States
- KROS United States
- Employees
- NVTS N/A
- KROS N/A
- Industry
- NVTS Semiconductors
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- NVTS Technology
- KROS Health Care
- Exchange
- NVTS Nasdaq
- KROS Nasdaq
- Market Cap
- NVTS 535.2M
- KROS 460.6M
- IPO Year
- NVTS N/A
- KROS 2020
- Fundamental
- Price
- NVTS $3.17
- KROS $11.02
- Analyst Decision
- NVTS Strong Buy
- KROS Buy
- Analyst Count
- NVTS 7
- KROS 11
- Target Price
- NVTS $4.39
- KROS $45.33
- AVG Volume (30 Days)
- NVTS 3.6M
- KROS 1.0M
- Earning Date
- NVTS 02-24-2025
- KROS 03-03-2025
- Dividend Yield
- NVTS N/A
- KROS N/A
- EPS Growth
- NVTS N/A
- KROS N/A
- EPS
- NVTS N/A
- KROS N/A
- Revenue
- NVTS $91,381,000.00
- KROS $651,000.00
- Revenue This Year
- NVTS $8.34
- KROS $303.27
- Revenue Next Year
- NVTS $5.50
- KROS N/A
- P/E Ratio
- NVTS N/A
- KROS N/A
- Revenue Growth
- NVTS 38.99
- KROS 8037.50
- 52 Week Low
- NVTS $1.75
- KROS $9.78
- 52 Week High
- NVTS $7.40
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- NVTS 50.17
- KROS 33.50
- Support Level
- NVTS $2.68
- KROS $10.09
- Resistance Level
- NVTS $3.62
- KROS $12.05
- Average True Range (ATR)
- NVTS 0.24
- KROS 0.44
- MACD
- NVTS 0.05
- KROS 0.73
- Stochastic Oscillator
- NVTS 52.13
- KROS 47.45
About NVTS Navitas Semiconductor Corporation
Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components for use in mobile device and other markets. Geographically, the company operates in China, Europe, United States, Rest of Asia and Others. The majority of revenue is generated from China.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.